Amplia Therapeutics (ATX) Stock Overview
A clinical-stage drug development company, engages in the development of focal adhesion kinase (FAK) inhibitors for cancer and fibrosis in Australia. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
ATX Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
100% Patient Improvement in trial puts this $16M Biotech on the radar
Key Takeaways Hoth is a clinical-stage biotech with a diversified pipeline across oncology, neurology, and inflammation. Lead drug HT-001 targets cancer treatment related rashes, a multi-hundred-million-dollar niche where no approved therapies exist.
Amplia Therapeutics Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.17 |
| 52 Week High | AU$0.42 |
| 52 Week Low | AU$0.049 |
| Beta | 0.67 |
| 1 Month Change | 3.13% |
| 3 Month Change | -44.07% |
| 1 Year Change | 10.00% |
| 3 Year Change | 65.00% |
| 5 Year Change | -8.33% |
| Change since IPO | -91.75% |
Recent News & Updates
Recent updates
We Think Amplia Therapeutics (ASX:ATX) Needs To Drive Business Growth Carefully
Jan 13
Companies Like Amplia Therapeutics (ASX:ATX) Are In A Position To Invest In Growth
Apr 28Amplia Therapeutics Limited (ASX:ATX) Insiders Increased Their Holdings
Feb 28Companies Like Amplia Therapeutics (ASX:ATX) Are In A Position To Invest In Growth
Jan 06
Shareholder Returns
| ATX | AU Biotechs | AU Market | |
|---|---|---|---|
| 7D | 10.0% | 7.2% | 2.3% |
| 1Y | 10.0% | -25.7% | 10.1% |
Return vs Industry: ATX exceeded the Australian Biotechs industry which returned -25.7% over the past year.
Return vs Market: ATX matched the Australian Market which returned 10.1% over the past year.
Price Volatility
| ATX volatility | |
|---|---|
| ATX Average Weekly Movement | 15.6% |
| Biotechs Industry Average Movement | 11.9% |
| Market Average Movement | 9.3% |
| 10% most volatile stocks in AU Market | 19.7% |
| 10% least volatile stocks in AU Market | 3.4% |
Stable Share Price: ATX's share price has been volatile over the past 3 months compared to the Australian market.
Volatility Over Time: ATX's weekly volatility has decreased from 31% to 16% over the past year, but is still higher than 75% of Australian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | n/a | Chris Burns | www.ampliatx.com |
Amplia Therapeutics Limited, a clinical-stage drug development company, engages in the development of focal adhesion kinase (FAK) inhibitors for cancer and fibrosis in Australia. Its product pipeline comprises Narmafotinib (AMP945), an inhibitor of FAK, which is in 1b/2a clinical trial for pancreatic cancer; and treatment of idiopathic pulmonary fibrosis, as well as ovarian cancer. It also develops AMP886 for application in oncology and chronic fibrosis indications.
Amplia Therapeutics Limited Fundamentals Summary
| ATX fundamental statistics | |
|---|---|
| Market cap | AU$84.66m |
| Earnings (TTM) | -AU$6.57m |
| Revenue (TTM) | AU$3.78m |
Is ATX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ATX income statement (TTM) | |
|---|---|
| Revenue | AU$3.78m |
| Cost of Revenue | AU$210.57k |
| Gross Profit | AU$3.57m |
| Other Expenses | AU$10.15m |
| Earnings | -AU$6.57m |
Last Reported Earnings
Mar 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.013 |
| Gross Margin | 94.43% |
| Net Profit Margin | -173.69% |
| Debt/Equity Ratio | 0% |
How did ATX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/10/04 19:37 |
| End of Day Share Price | 2025/10/03 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2025/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Amplia Therapeutics Limited is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Thomas Wakim | Bell Potter |